Mitochondrial	B-Cellular_component
apoptosis	O
and	O
FAK	O
signaling	O
disruption	O
by	O
a	O
novel	O
histone	O
deacetylase	O
inhibitor	O
,	O
HTPB	O
,	O
in	O
antitumor	B-Cancer
and	O
antimetastatic	O
mouse	O
models	O
.	O

BACKGROUND	O
:	O
Compound	O
targeting	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
represents	O
a	O
new	O
era	O
in	O
molecular	O
cancer	B-Cancer
therapeutics	O
.	O

However	O
,	O
effective	O
HDAC	O
inhibitors	O
for	O
the	O
treatment	O
of	O
solid	B-Cancer
tumors	I-Cancer
remain	O
to	O
be	O
developed	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Here	O
,	O
we	O
propose	O
a	O
novel	O
HDAC	O
inhibitor	O
,	O
N	O
-	O
Hydroxy	O
-	O
4	O
-	O
(	O
4	O
-	O
phenylbutyryl	O
-	O
amino	O
)	O
benzamide	O
(	O
HTPB	O
)	O
,	O
as	O
a	O
potential	O
chemotherapeutic	O
drug	O
for	O
solid	B-Cancer
tumors	I-Cancer
.	O

The	O
HDAC	O
inhibition	O
of	O
HTPB	O
was	O
confirmed	O
using	O
HDAC	O
activity	O
assay	O
.	O

The	O
antiproliferative	O
and	O
anti	O
-	O
migratory	O
mechanisms	O
of	O
HTPB	O
were	O
investigated	O
by	O
cell	B-Cell
proliferation	O
,	O
flow	O
cytometry	O
,	O
DNA	O
ladder	O
,	O
caspase	O
activity	O
,	O
Rho	O
activity	O
,	O
F	O
-	O
actin	O
polymerization	O
,	O
and	O
gelatin	O
-	O
zymography	O
for	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
.	O

Mice	O
with	O
tumor	B-Cancer
xenograft	I-Cancer
and	O
experimental	O
metastasis	O
model	O
were	O
used	O
to	O
evaluate	O
effects	O
on	O
tumor	B-Cancer
growth	O
and	O
metastasis	O
.	O

Our	O
results	O
indicated	O
that	O
HTPB	O
was	O
a	O
pan	O
-	O
HDAC	O
inhibitor	O
in	O
suppressing	O
cell	B-Cell
viability	O
specifically	O
of	O
lung	B-Cell
cancer	I-Cell
cells	I-Cell
but	O
not	O
of	O
the	O
normal	O
lung	B-Cell
cells	I-Cell
.	O

Upon	O
HTPB	O
treatment	O
,	O
cell	B-Cell
cycle	O
arrest	O
was	O
induced	O
and	O
subsequently	O
led	O
to	O
mitochondria	B-Cellular_component
-	O
mediated	O
apoptosis	O
.	O

HTPB	O
disrupted	O
F	O
-	O
actin	O
dynamics	O
via	O
downregulating	O
RhoA	O
activity	O
.	O

Moreover	O
,	O
HTPB	O
inhibited	O
activity	O
of	O
MMP2	O
and	O
MMP9	O
,	O
reduced	O
integrin	O
-	O
beta1	O
/	O
focal	O
adhesion	O
complex	O
formation	O
and	O
decreased	O
pericellular	B-Immaterial_anatomical_entity
poly	O
-	O
fibronectin	O
assemblies	O
.	O

Finally	O
,	O
intraperitoneal	B-Immaterial_anatomical_entity
injection	O
or	O
oral	B-Organism_subdivision
administration	O
of	O
HTPB	O
efficiently	O
inhibited	O
A549	B-Cancer
xenograft	I-Cancer
tumor	I-Cancer
growth	O
in	O
vivo	O
without	O
side	O
effects	O
.	O

HTPB	O
delayed	O
lung	B-Organ
metastasis	O
of	O
4T1	B-Cell
mouse	I-Cell
breast	I-Cell
cancer	I-Cell
cells	I-Cell
.	O

Acetylation	O
of	O
histone	O
and	O
non	O
-	O
histone	O
proteins	O
,	O
induction	O
of	O
apoptotic	O
-	O
related	O
proteins	O
and	O
de	O
-	O
phosphorylation	O
of	O
focal	O
adhesion	O
kinase	O
were	O
confirmed	O
in	O
treated	O
mice	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
These	O
results	O
suggested	O
that	O
intrinsic	O
apoptotic	O
pathway	O
may	O
involve	O
in	O
anti	O
-	O
tumor	B-Cancer
growth	O
effects	O
of	O
HTPB	O
in	O
lung	B-Cell
cancer	I-Cell
cells	I-Cell
.	O

HTPB	O
significantly	O
suppresses	O
tumor	B-Cancer
metastasis	O
partly	O
through	O
inhibition	O
of	O
integrin	O
-	O
beta1	O
/	O
FAK	O
/	O
MMP	O
/	O
RhoA	O
/	O
F	O
-	O
actin	O
pathways	O
.	O

We	O
have	O
provided	O
convincing	O
preclinical	O
evidence	O
that	O
HTPB	O
is	O
a	O
potent	O
HDAC	O
targeted	O
inhibitor	O
and	O
is	O
thus	O
a	O
promising	O
candidate	O
for	O
lung	B-Cancer
cancer	I-Cancer
chemotherapy	O
.	O

